- A radiograph of a patient's hand reveals significant juxta-articular osteopenia and marginal erosions. In contrast, a radiograph of another patient's knee shows subchondral sclerosis and osteophyte formation. What fundamental difference in pathophysiology accounts for these distinct bone changes?
Answer: RA involves RANKL-mediated osteoclast activation leading to bone resorption, while OA involves a reactive, reparative bone formation in response to altered joint mechanics.
In rheumatoid arthritis (RA), inflammatory cytokines (like TNF-α) stimulate synovial cells to express RANKL, which promotes the differentiation and activity of osteoclasts, leading to bone resorption (osteopenia and erosions). In osteoarthritis (OA), the loss of cartilage alters mechanical stress on the subchondral bone, which responds by increasing its density (sclerosis) and forming osteophytes at the joint margins in a reparative, albeit dysfunctional, attempt.
- Which of the following represents the most accurate distinction between the initiating cellular events in osteoarthritis versus rheumatoid arthritis?
Answer: OA begins with chondrocyte distress and dysfunctional repair, while RA begins with an immune cell-mediated attack on the synovium.
The fundamental difference lies in the initiating tissue and cell type. Osteoarthritis is primarily a disease of the cartilage, initiated by chondrocyte responses to mechanical and biochemical stress, leading to an imbalance in matrix degradation and synthesis. Rheumatoid arthritis is primarily a disease of the synovium, initiated by an autoimmune response where lymphocytes and other immune cells target the synovial lining.
- In advanced osteoarthritis, the subchondral bone often exhibits eburnation, appearing dense and polished. This pathological change is a direct result of:
Answer: loss of the overlying cartilage, leading to bone-on-bone friction and reactive sclerosis.
When you encounter questions about osteoarthritis pathology, focus on the progressive nature of cartilage destruction and the bone's compensatory responses.
Eburnation represents the end-stage pathological change in osteoarthritis where subchondral bone becomes exposed, dense, and ivory-like in appearance. This occurs because the protective articular cartilage has been completely worn away through mechanical stress and enzymatic degradation. Without this cushioning layer, bones directly contact each other during joint movement, creating friction that polishes the bone surface to a smooth, shiny appearance. The bone responds to this abnormal stress by increasing density (sclerosis) as osteoblasts deposit new bone matrix faster than osteoclasts can remove it.
Option A incorrectly describes a rheumatoid arthritis mechanism, where immune complexes do contribute to joint destruction, but they don't cause the specific eburnation pattern seen in osteoarthritis. Option B describes pannus formation, which is characteristic of inflammatory arthritides like rheumatoid arthritis, not the degenerative process of osteoarthritis. Option D misrepresents the RANKL pathway - while osteoclast activity does change in osteoarthritis, eburnation results from mechanical factors and reactive bone formation, not primarily from RANKL-mediated osteoclast inhibition.
Remember that osteoarthritis is fundamentally a "wear-and-tear" disease. When you see terms like "eburnation," "bone-on-bone contact," or "subchondral sclerosis," think mechanical consequences of cartilage loss rather than inflammatory or immunological processes.
- The presence of anti-citrullinated protein antibodies (ACPAs) is highly specific for rheumatoid arthritis. The formation of these antibodies is contingent on the post-translational modification of arginine residues to citrulline. This process is pathophysiologically significant because:
Answer: citrullinated proteins are recognized as neoantigens by the immune system, breaking self-tolerance and driving the autoimmune response.
Citrullination, catalyzed by peptidylarginine deiminase (PAD) enzymes, changes the structure of self-proteins (e.g., vimentin, fibrinogen). In genetically susceptible individuals (e.g., with certain HLA-DR alleles), these modified proteins are no longer recognized as 'self'. They are treated as foreign antigens, leading to the activation of T and B cells and the production of ACPAs, which perpetuates the autoimmune cycle in RA.
- Tumor Necrosis Factor-alpha (TNF-α) is a key cytokine in both OA and RA, but biologic therapies targeting TNF-α are dramatically more effective in RA. This difference in efficacy is primarily because in RA, TNF-α:
Answer: is a central upstream driver of the entire inflammatory cascade, including IL-1 and IL-6 production and pannus formation.
In rheumatoid arthritis, TNF-α is a master cytokine produced by macrophages and T-cells in the synovium. It sits at the top of the inflammatory cascade, driving the production of other key cytokines (IL-1, IL-6), promoting angiogenesis, activating destructive synovial fibroblasts, and stimulating RANKL expression. In osteoarthritis, TNF-α is present and contributes to inflammation and cartilage degradation, but it is not the central, upstream driver of the entire disease process to the same extent; the primary driver in OA is mechanical.
- A defining feature of the fibroblast-like synoviocytes (FLS) in a rheumatoid arthritis joint is their transformation into an aggressive, tumor-like phenotype. This transformation is pathologically significant because these activated FLS:
Answer: become the primary cellular component of the invasive pannus and directly mediate cartilage and bone destruction.
When you encounter questions about rheumatoid arthritis pathophysiology, focus on the central role of activated fibroblast-like synoviocytes (FLS) in joint destruction. These cells undergo a dramatic transformation that drives the disease's aggressive nature.
In healthy joints, FLS maintain the synovial membrane and produce synovial fluid. However, in rheumatoid arthritis, chronic inflammation transforms these cells into an aggressive, tumor-like phenotype. These activated FLS become the dominant cellular component of the pannus - a destructive tissue that grows like a tumor over joint surfaces. The pannus directly invades and destroys both cartilage and underlying bone through several mechanisms: FLS secrete matrix metalloproteinases (MMPs) that degrade cartilage matrix, produce RANKL that activates osteoclasts for bone resorption, and physically invade joint structures. This makes option C correct - these transformed cells are literally the "teeth" of joint destruction.
Option A is incorrect because FLS don't differentiate into chondrocytes; they remain fibroblast-like cells that destroy rather than produce cartilage. Option B misrepresents what happens - these cells actually resist apoptosis and proliferate aggressively, which is part of their tumor-like behavior. Option D confuses cell types; rheumatoid factor is primarily produced by plasma cells (activated B-cells), not FLS, though FLS do secrete inflammatory cytokines.
Remember this key concept: in rheumatoid arthritis, think of activated FLS as the "cellular destroyers" that form the invasive pannus. This tumor-like tissue is what physically eats away at your joints.
- A synovial biopsy is taken from a patient with chronic joint pain. Histological analysis reveals extensive infiltration of the synovial membrane with lymphocytes and plasma cells, alongside marked synovial hyperplasia. This finding is most indicative of rheumatoid arthritis rather than osteoarthritis because it points to:
Answer: a primary autoimmune process targeting the synovium as the disease initiator.
The key pathophysiological distinction is the initiating event. In rheumatoid arthritis (RA), the disease begins as a primary autoimmune attack on the synovial membrane, characterized by infiltration of immune cells like lymphocytes and plasma cells, leading to synovitis and hyperplasia. In osteoarthritis (OA), synovial inflammation is typically a secondary, milder reaction to cartilage breakdown products, not the primary cause of the disease.
- A patient with osteoarthritis of the knee experiences a flare of pain and swelling. Analysis of the synovial fluid would most likely reveal findings consistent with a reactive, low-grade inflammation. How does this differ from the typical synovial fluid findings in an untreated, active rheumatoid arthritis flare?
Answer: RA fluid shows much higher cell counts, lower viscosity, and a poorer mucin clot due to intense, primary synovial inflammation.
RA is a highly inflammatory arthritis. This is reflected in the synovial fluid by a high white blood cell count (often >2,000-50,000 cells/μL, mostly neutrophils), and inflammation-mediated degradation and dilution of hyaluronic acid, which leads to low viscosity and a poor mucin clot. In contrast, OA is considered non-inflammatory or mildly inflammatory, with lower cell counts (<2,000 cells/μL), high viscosity, and a firm mucin clot, reflecting a healthier state of hyaluronic acid.
- In the very early stages of its pathophysiology, osteoarthritis is characterized by a temporary, ineffective anabolic response from chondrocytes (e.g., formation of cell clusters or 'clones'). This initial attempt at repair is a key distinction from the earliest detectable pathophysiological event in rheumatoid arthritis, which is:
Answer: a subclinical, asymptomatic synovitis involving infiltration of the synovial lining by immune cells.
When comparing osteoarthritis and rheumatoid arthritis pathophysiology, you need to understand that these are fundamentally different disease processes with distinct initiating events, even though both ultimately affect joints.
The question highlights that osteoarthritis begins with chondrocytes attempting repair through anabolic responses like forming cell clusters. This is a mechanical wear-and-tear process where cartilage tries to fix itself initially. In contrast, rheumatoid arthritis is an autoimmune inflammatory disease that starts in the synovium, not the cartilage.
The correct answer is B because rheumatoid arthritis begins with subclinical synovitis - immune cells (primarily T-cells, B-cells, and macrophages) infiltrate the synovial membrane before any symptoms appear. This inflammatory infiltration occurs months or even years before joint pain or swelling becomes noticeable, making it the earliest detectable pathophysiological event.
A is incorrect because microfractures in subchondral bone are actually seen in osteoarthritis, not rheumatoid arthritis - this describes the wrong disease entirely.
C is wrong because while enzyme-mediated cartilage degradation does occur in RA, it's a later consequence of the synovial inflammation, not the initiating event.
D is incorrect because genetic proteoglycan deficiency describes a developmental cartilage disorder, not an acquired autoimmune disease like RA.
Study tip: Remember the fundamental distinction - osteoarthritis starts with cartilage trying to repair mechanical damage, while rheumatoid arthritis starts with immune system activation in the synovium. The timeline matters: RA's synovial inflammation precedes symptoms, while OA's chondrocyte clustering follows initial cartilage damage.
- Both osteoarthritis and rheumatoid arthritis involve the action of matrix metalloproteinases (MMPs) in cartilage destruction. What is a key difference in the primary stimulus for MMP production in these two diseases?
Answer: In OA, MMPs are primarily produced by stressed chondrocytes, while in RA, they are massively upregulated in synovial cells by pro-inflammatory cytokines.
When you encounter questions comparing osteoarthritis (OA) and rheumatoid arthritis (RA), focus on their fundamental difference: OA is primarily a mechanical/degenerative disease, while RA is an autoimmune inflammatory condition. This distinction drives how matrix metalloproteinases (MMPs) are produced and regulated in each disease.
The correct answer is D because it captures this core pathophysiologic difference. In OA, cartilage breakdown begins when chondrocytes respond to mechanical stress, aging, or minor trauma by producing MMPs as part of attempted repair. In RA, the inflamed synovium becomes a "pannus" that aggressively produces MMPs in response to inflammatory cytokines like TNF-α, IL-1, and IL-6. The synovial tissue essentially becomes a destructive factory pumping out these enzymes.
Option A is wrong because MMPs target cartilage in both diseases, though RA additionally causes bone erosions through other mechanisms. Option B incorrectly identifies the cellular sources - while neutrophils do contribute MMPs in RA, synovial cells are the major source, and osteoclasts aren't the primary MMP producers in OA. Option C misrepresents TIMP regulation - both diseases show imbalanced MMP/TIMP ratios, but RA patients aren't genetically deficient in TIMPs.
Remember this pattern: OA questions often involve mechanical stress and chondrocyte responses, while RA questions center on inflammatory cascades and synovial pathology. Understanding the cellular source and stimulus for tissue destruction helps you distinguish between degenerative versus inflammatory joint diseases on pathophysiology exams.
- The formation of a pannus is a pathognomonic feature of rheumatoid arthritis. Which statement best describes the direct role of this structure in joint destruction?
Answer: It secretes matrix metalloproteinases and other enzymes that directly erode adjacent articular cartilage and subchondral bone.
The pannus is a mass of hypertrophied synovial tissue, inflammatory cells, and fibroblasts. Its defining pathological feature is its invasive and destructive nature. It adheres to the articular cartilage and secretes proteolytic enzymes, such as matrix metalloproteinases (MMPs), which directly degrade the cartilage matrix and erode the underlying bone.
- A patient with osteoarthritis has pain that worsens with activity and improves with rest. A patient with rheumatoid arthritis has pain and stiffness that is worst in the morning and improves with activity. This clinical difference is best explained by which pathophysiological mechanism?
Answer: In RA, inflammatory mediators accumulate in the joint overnight, causing stiffness that is relieved as circulation improves with movement.
When analyzing joint pain patterns in arthritis, focus on the underlying pathophysiology driving each condition—mechanical wear versus inflammatory processes.
In rheumatoid arthritis, the synovium becomes chronically inflamed and thickened due to autoimmune attack. During periods of inactivity (like overnight sleep), inflammatory mediators such as cytokines, prostaglandins, and leukotrienes accumulate in the joint space. Blood flow is also reduced during rest, allowing these inflammatory substances to concentrate. When you begin moving in the morning, increased circulation helps clear these mediators while mechanical movement stimulates synovial fluid production and distribution, gradually reducing stiffness and pain. This explains why RA patients experience morning stiffness that improves with activity—making option B correct.
Option A describes osteoarthritis accurately but doesn't explain RA's morning stiffness pattern. In OA, cartilage degradation does cause mechanical pain that worsens with weight-bearing activity, but this doesn't address the inflammatory accumulation mechanism in RA.
Option C incorrectly identifies muscle spasms as RA's primary pain source. While muscle tension can occur secondary to joint inflammation, RA pain stems from synovial inflammation, not muscle spasms. Nerve entrapment by osteophytes can occur in OA but isn't the primary pain mechanism.
Option D misrepresents synovial fluid dynamics. In both conditions, movement actually helps maintain normal synovial fluid viscosity and distribution—it doesn't worsen lubrication.
Remember: OA = mechanical wear (worse with use), RA = inflammatory (worse after rest due to mediator accumulation). The timing pattern directly reflects the underlying pathophysiology.
- Histological examination of a joint from a patient with end-stage rheumatoid arthritis would most likely reveal:
Answer: replacement of the articular surface by an inflammatory fibrovascular pannus and significant subchondral bone erosion.
When examining joint pathology, you need to distinguish between the characteristic features of different arthritides, particularly rheumatoid arthritis versus osteoarthritis.
Rheumatoid arthritis is fundamentally an inflammatory autoimmune disease targeting the synovium. The hallmark pathological feature is pannus formation - an inflammatory, fibrovascular tissue that grows from the inflamed synovium and literally "eats away" at cartilage and underlying bone. This pannus replaces normal articular surfaces and causes the characteristic bone erosions seen on X-rays. The inflammatory process is so aggressive that it erodes through cartilage into subchondral bone, creating the joint destruction that defines end-stage disease.
Option A describes osteoarthritis, not rheumatoid arthritis. Eburnation (polished, ivory-like bone) and osteophytes (bone spurs) are classic osteoarthritic changes resulting from mechanical wear-and-tear, not inflammatory destruction.
Option C describes gout, where monosodium urate crystals deposit in joints and trigger acute inflammatory episodes. This crystal arthropathy has a completely different pathophysiology from rheumatoid arthritis.
Option D is incorrect because rheumatoid arthritis destroys hyaline cartilage - it doesn't regenerate it. The synovium becomes hyperplastic and inflamed rather than destroyed.
Study tip: Remember that rheumatoid arthritis = inflammatory pannus formation with bone erosions, while osteoarthritis = mechanical wear with bone spurs and eburnation. The presence of inflammatory tissue replacing normal joint architecture always points toward rheumatoid arthritis in pathology questions.
- A 68-year-old patient with obesity and knee pain is diagnosed with osteoarthritis. A 38-year-old patient develops bilateral, symmetric hand pain and is diagnosed with rheumatoid arthritis. The initiating pathogenic event in the first patient is primarily biomechanical/metabolic, while in the second patient it is primarily:
Answer: an immunological event involving a loss of self-tolerance to modified synovial antigens.
This question tests your understanding of the fundamental pathogenic mechanisms underlying different types of arthritis. When you encounter arthritis questions, always consider whether the disease stems from mechanical wear, autoimmune processes, infection, or other causes.
Rheumatoid arthritis is a classic autoimmune disease where the body's immune system mistakenly attacks its own tissues. The initiating event involves molecular mimicry or other triggers that cause immune cells to lose tolerance to self-antigens, particularly citrullinated proteins in synovial tissue. This leads to chronic inflammation, synovial proliferation, and joint destruction through activated T-cells, B-cells, and inflammatory cytokines like TNF-α and IL-1.
Let's examine why the other options are incorrect:
A) While septic arthritis does involve direct pathogen seeding, rheumatoid arthritis is not primarily an infectious disease. Though some infections may trigger autoimmune responses, the ongoing pathology is immune-mediated, not infectious.
B) Vascular events with microthrombi are not the primary mechanism in RA. While vasculitis can occur as a complication of established RA, ischemia from thrombosis is not the initiating pathogenic event.
D) Neurological sensitization describes pain amplification mechanisms but not the underlying disease process. While RA patients experience pain, peripheral receptor sensitization is a consequence of inflammation, not the root cause of joint damage.
Remember this pattern: osteoarthritis = mechanical/metabolic damage; rheumatoid arthritis = autoimmune attack on synovium. The bilateral, symmetric presentation in young adults strongly suggests autoimmune etiology rather than wear-and-tear mechanics.
- The symmetric involvement of small joints (MCPs, PIPs) is a classic feature of rheumatoid arthritis. This pattern is a direct consequence of which pathophysiological aspect of the disease?
Answer: The systemic dissemination of autoantigens, autoantibodies, and activated immune cells via the bloodstream to multiple synovial joints.
When you encounter questions about rheumatoid arthritis (RA) joint patterns, focus on the underlying immune mechanisms that drive this autoimmune disease. The hallmark symmetric involvement of small joints isn't coincidental—it reflects how the disease spreads throughout the body.
The correct answer is D because RA is fundamentally an autoimmune disease where your immune system attacks your own synovial tissue. Once this autoimmune response is triggered, autoantigens (self-proteins perceived as foreign), autoantibodies (like rheumatoid factor and anti-CCP), and activated immune cells circulate systemically through your bloodstream. Since blood reaches all synovial joints equally, the inflammatory process affects joints symmetrically. This explains why RA typically involves the same joints on both sides of your body simultaneously.
Option A is incorrect because RA isn't a developmental cartilage defect—it's an acquired autoimmune condition that primarily targets synovium, not cartilage initially. Option B oversimplifies the etiology; while infections may trigger RA in genetically susceptible individuals, the symmetric pattern isn't due to viral tropism but rather systemic immune activation. Option C misses the mark entirely—mechanical stress would cause asymmetric wear patterns based on hand dominance and usage, not the bilateral symmetry characteristic of RA.
Remember that autoimmune diseases create systemic inflammation through blood-borne mediators. When you see symmetric joint involvement, think "systemic autoimmune process" rather than local mechanical or developmental causes. This principle applies to other autoimmune arthritides as well, helping you distinguish them from degenerative or infectious joint diseases.
- A novel therapeutic agent is developed that specifically enhances the synthesis of type II collagen and aggrecan by chondrocytes. Why would this drug likely show more promise as a disease-modifying agent in early osteoarthritis than in established rheumatoid arthritis?
Answer: In RA, the primary problem is uncontrolled synovial inflammation which would destroy any newly synthesized cartilage regardless of chondrocyte activity.
When evaluating disease-modifying therapies for joint diseases, you need to understand the fundamental differences between osteoarthritis (OA) and rheumatoid arthritis (RA) pathophysiology. OA is primarily a degenerative cartilage disease, while RA is an autoimmune inflammatory condition.
The correct answer is D because RA's hallmark feature is aggressive synovial inflammation that creates a hostile environment for cartilage. The inflamed synovium produces inflammatory cytokines (TNF-α, IL-1β, IL-6) and matrix metalloproteinases that actively degrade cartilage matrix components, including type II collagen and aggrecan. Even if this drug successfully stimulated chondrocytes to produce more cartilage building blocks, the ongoing inflammatory cascade would immediately destroy these newly synthesized components. It's like trying to build a sand castle while someone continuously pours water on it.
Choice A is incorrect because pannus (inflamed synovial tissue) doesn't attempt to form cartilage—it actually invades and destroys cartilage at joint margins. Choice B misunderstands OA pathophysiology; chondrocytes remain present in early OA, though they may become dysfunctional. This drug wouldn't repopulate cells but enhance existing chondrocyte function. Choice C incorrectly suggests RA involves overproduction of dysfunctional collagen, when the actual problem is inflammatory destruction of normal cartilage matrix.
Study tip: Remember that RA requires controlling inflammation first before any cartilage-protective therapy can be effective. Always consider whether the underlying disease mechanism would counteract the proposed therapeutic intervention.
- A new drug is developed that potently inhibits RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand). This drug would be most effective at preventing which specific pathological feature of arthritis?
Answer: The formation of bony erosions in rheumatoid arthritis by preventing osteoclast activation.
When you encounter questions about bone remodeling drugs, focus on the specific pathway being targeted and which bone cells are affected. RANKL is a crucial signaling molecule in the RANK/RANKL/OPG pathway that specifically controls osteoclast function.
RANKL (produced by osteoblasts and immune cells) binds to RANK receptors on osteoclast precursors, triggering their differentiation into mature, bone-resorbing osteoclasts. By inhibiting RANKL, this drug would prevent osteoclast activation and subsequent bone destruction. In rheumatoid arthritis, inflammatory cytokines dramatically upregulate RANKL production, leading to excessive osteoclast activity and the characteristic bony erosions that cause permanent joint damage. Therefore, answer C is correct.
Here's why the other options are wrong: Option A targets metalloproteinases, which are enzymes that degrade cartilage matrix, but RANKL inhibition doesn't affect these enzymes—it specifically targets bone cells, not cartilage degradation. Option B involves osteoblast activity and osteophyte formation, but RANKL primarily regulates osteoclasts, not osteoblasts, so this drug wouldn't prevent abnormal bone growth. Option D suggests RANKL inhibition affects T-cell function and synovial inflammation, but while immune cells do produce RANKL, the drug's primary therapeutic effect is on bone resorption, not initial inflammatory responses.
Study tip: Remember that RANKL = osteocLast activation. The "L" in both can help you recall this connection. When you see RANKL inhibitors like denosumab in clinical contexts, they're specifically targeting bone destruction, not cartilage damage or inflammation.
- A patient with long-standing rheumatoid arthritis develops fibrous ankylosis of the wrist. This complication is a direct consequence of:
Answer: the pannus destroying the articular cartilage and bridging the joint space with fibrous tissue.
When you encounter questions about joint complications in rheumatoid arthritis, focus on the distinctive pathological process that sets RA apart from other arthritides: pannus formation and its destructive effects.
In rheumatoid arthritis, chronic synovial inflammation leads to the formation of pannus—an aggressive, inflamed synovial tissue that grows like a tumor. This pannus directly attacks and destroys articular cartilage through enzymatic degradation and mechanical invasion. As the pannus progressively destroys cartilage and extends across the joint space, it eventually becomes fibrotic, creating fibrous bridges that connect the opposing bone surfaces. This fibrous tissue literally fills and spans the joint space, resulting in fibrous ankylosis—the hallmark complication described in this question.
Option A incorrectly attributes ankylosis to subchondral bone collapse from osteoporosis. While juxta-articular osteoporosis does occur in RA, it doesn't cause joint fusion—it actually weakens the bone structure. Option C describes osteophyte formation, which is characteristic of osteoarthritis, not rheumatoid arthritis. RA typically causes bone erosion rather than bone overgrowth. Option D suggests muscle contracture as the cause, but while muscle atrophy and weakness occur in RA, they don't create true bony or fibrous ankylosis.
Remember this key distinction: in RA pathophysiology questions, look for processes involving pannus formation and cartilage destruction. The pannus is the "villain" in RA—it's what makes this disease so uniquely destructive compared to other forms of arthritis.
- A strong genetic association with certain Human Leukocyte Antigen (HLA) class II molecules, such as HLA-DR4, is a major risk factor for rheumatoid arthritis but not osteoarthritis. This specific genetic link points to a key pathophysiological mechanism involving:
Answer: aberrant presentation of arthritogenic peptides to autoreactive CD4+ T-helper cells.
When you encounter questions linking specific HLA alleles to autoimmune diseases, you're dealing with adaptive immunity and antigen presentation mechanisms. HLA class II molecules are crucial for presenting processed antigens to CD4+ T cells, and certain HLA variants create perfect conditions for autoimmune responses.
The strong association between HLA-DR4 and rheumatoid arthritis points directly to aberrant antigen presentation. HLA-DR4 molecules have a unique binding groove structure that can present joint-derived "arthritogenic" peptides (like citrullinated proteins) to CD4+ T-helper cells. This inappropriate presentation triggers autoreactive T cells to mount an immune response against the body's own joint tissues, initiating the chronic inflammatory cascade characteristic of RA. This explains why RA is fundamentally an autoimmune disease driven by adaptive immunity.
Option A is incorrect because HLA associations point to adaptive, not innate immunity. Innate responses don't require specific HLA molecules for antigen presentation. Option B misses the mark entirely—HLA genes encode immune proteins, not structural cartilage components like collagen. The genetic link is immunological, not mechanical. Option C about synovial fibroblast senescence doesn't explain the HLA connection at all, as these molecules function in immune recognition, not cellular aging processes.
Remember this pattern: when you see strong HLA class II associations with autoimmune diseases, think "aberrant antigen presentation to CD4+ T cells." This mechanism distinguishes autoimmune arthritis (RA) from degenerative joint disease (osteoarthritis), which lacks these genetic immune associations.
